Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Pfizer Florida Medicaid Accounting Will Be Ready In March; Is Texas Next?

  • News

Executive Summary

Pfizer plans to submit a first-year report on its Florida Medicaid disease management program to the state in mid-March

You may also be interested in...



Florida Gets 36% Raise From Pfizer Under New Disease Management Contract

Pfizer's contract extension with Florida provides a 36% increase in savings from disease management programs over the previous agreement

Florida Gets 36% Raise From Pfizer Under New Disease Management Contract

Pfizer's contract extension with Florida provides a 36% increase in savings from disease management programs over the previous agreement

Pfizer Message To Michigan: Access, Not Taxes, Will Influence Employment

Pfizer's decision about the future of the former Upjohn campus in Michigan provides an opportunity for the company to renew its push for changes to the state's Medicaid program

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By